Targeted axillary dissection (TAD) is a relatively new breast cancer procedure. It allows surgical oncologists to specifically locate a lymph node that contained cancer before chemotherapy, remove it ...

Targeted axillary dissection (TAD) emerged as the optimal minimally invasive technique, demonstrating superior diagnostic accuracy over other approaches in patients with node-positive breast cancer ...

Skipping standard axillary lymph node dissection led to very low rates of axillary recurrence in patients with node-positive breast cancer who became node-negative following neoadjuvant chemotherapy, ...

MIAMI BEACH -- The surgical dogma favoring axillary dissection in breast cancer continues to give way to more selective data-driven strategies that allow more women to avoid axillary surgery, an ...

Please provide your email address to receive an email when new articles are posted on . SAN ANTONIO — Omission of completion axillary lymph node dissection did not increase recurrence among patients ...

Trials evaluating the omission of completion axillary-lymph-node dissection in patients with clinically node-negative breast cancer and sentinel-lymph-node metastases have been compromised by limited ...

Extensive removal of lymph nodes in the area surrounding the breast and in the armpit — a strategy designed to prevent the spread of cancer cells to the rest of the body — appears unnecessary for many ...

Patients with breast cancer may be able to avoid lymphedema, which can occur after surgery to remove lymph nodes in the ...

Patients with lymph node-positive breast cancer may still avoid extensive axillary surgery if they have clear nodes after systemic therapy, data from a prospective registry showed. Patients with clear ...

A total of 751 women clinically node negative post-NACT underwent LAS (excision of lymph node [LN] and fat below first intercostobrachial nerve). Of these women, 730 also underwent SNB by dual ...

Comparison of operative to monitoring and endocrine therapy for low-risk DCIS (COMET study). NRG Oncology/NSABP B-51/RTOG 1304: Phase III trial to determine if chest wall and regional nodal ...